Business Wire

ChipAgents Raises Oversubscribed $21M Series A to Redefine AI for Chip Design

21.10.2025 16:30:00 CEST | Business Wire | Press Release

Share

Today ChipAgents, the agentic AI platform transforming chip design and verification, announced the close of a $21 million Series A funding round, bringing the total fundraise to $24 million to date. This latest round closed with Bessemer Venture Partners, with strategic backing from Micron, MediaTek, Ericsson, and additional top semiconductor companies. Also participating in the round are notable angels including new advisors, Wally Rhines, Raúl Camposano,and Jack Harding, and existing support by ScOp Venture Capital (Ivan Bercovich) and Amino Capital, fueling the company’s expansion of product development, customer acquisition, and strategic industry partnerships.

ChipAgents’ mission is to bring the power of AI to the heart of chip design and verification. Every engineer should be empowered with tools that make the most complex aspects of hardware development faster, more intuitive, and dramatically more productive. Chips are the foundation of our digital world, yet the process of building and verifying them remains slow, costly, and labor-intensive. By rethinking workflows with AI, ChipAgents shortens design cycles, accelerates innovation, and helps semiconductor companies deliver breakthroughs that will shape the next decade of technology.

“Electronic design automation (EDA) has powered decades of semiconductor progress, but today’s engineers still struggle with fragmented toolchains, steep costs, and workflows that haven’t kept pace with rapidly growing chip complexity,” said Founder and CEO, Professor William Wang. “As designs scale, productivity gains have slowed and verification remains highly manual. Our vision is to change that. With ChipAgents, we’re introducing a unified agentic AI platform designed to automate routine tasks, accelerate design and verification, and enable AI-native workflows that help engineers focus on innovation rather than repetitive effort.”

Building on the momentum of its seed round, ChipAgents saw a 6,377% surge in monthly usage in the first half of 2025, leveraging agentic AI to accelerate RTL code generation, testbench creation, debugging, and verification through intuitive, language-based commands. The result: expedited time-to-market, cost reductions, and a redefined benchmark for productivity in chip development. Across independent teams, ChipAgents achieves 80% higher productivity in verification compared to industry practices and is deployed at 50 leading semiconductor companies, showcasing its ability to deliver real-world value at scale. The company sees a 50x YoY growth in annual recurring revenue (ARR) in the beginning of its second year.

"ChipAgents has demonstrated itself as having the best product in the market that does AI-powered RTL design, debugging, and verification for chip developers,” said Lance Co Ting Keh, Venture Partner at Bessemer Venture Partners. “We’re impressed by Professor William Wang’s deep technical expertise and the exceptional team of AI and hardware design experts he’s assembled. ChipAgents’ agentic approach to AI chip design integrates seamlessly across the entire chip design workflow, bringing together disparate EDA tools from spec ingestion to waveform analysis, which we believe is the right way to tackle this complex, multi-step process. The feedback from customers and technical experts validates that ChipAgents isn't just automating individual tasks, but creating a true force multiplier for hardware design engineers.”

“Micron Ventures supports bold AI companies led by visionary founders developing transformative technologies. ChipAgents’ mission to reinvent chip design through AI agents aligns closely with our focus, especially as chipmakers require faster, more intelligent design solutions to meet the accelerating demands of AI hardware. At this pivotal inflection point, ChipAgents presents a high-impact opportunity to invest in the future of semiconductor development,” said Henry Huang, Investment Director at Micron Ventures.

ChipAgents has also bolstered its leadership team with the formation of a world-class advisory board composed of several of the semiconductor industry’s most distinguished veterans. The new board includes Wally Rhines, former CEO of Mentor Graphics (now Siemens EDA); Raúl Camposano, former CTO of Synopsys; Jack Harding, former CEO of Cadence; and Erez Tsur, former CEO of Cadence Israel. Collectively, with additional guidance from founding advisor, Dr. John Bowers, these silicon luminaries bring decades of experience in building and scaling the very companies that have defined the EDA landscape.

"ChipAgents demonstrates the major impact that AI can have on the full range of integrated circuit design tasks,” said Wally Rhines. “I’ve met with three major semiconductor companies that have done competitive assessments of AI-based design solutions, and ChipAgents is the number one choice at all three.”

"ChipAgents is pioneering a new era in semiconductor design, where AI and engineering expertise converge for smarter solutions. The implications for the semiconductor industry are nothing short of transformative, and I’m excited to support their mission,” said Raúl Camposano.

Book a demo with ChipAgents to learn more about the agentic AI EDA platform, and check out the open positions to join the pioneering team.

About ChipAgents

ChipAgents is a cutting-edge AI startup delivering generative, agentic solutions for chip design and verification. Its flagship product transforms how hardware companies define, validate, and refine RTL code, simplifying complex workflows while driving unmatched productivity and accuracy. For more information, visit ChipAgents.ai or follow us on LinkedIn and Twitter/X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251021677325/en/

Contacts

Media Contact:
press@alphadesign.ai

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye